fluciclovine F-18

A radioactive diagnostic agent used for the detection of recurrent prostate cancer by POSITRON EMISSION TOMOGRAPHY; structure in first source.

Also Known As:

(18F)GE-148; (1R,3R)-1-amino-3(18F)fluorocyclobutane-1-carboxylic acid; 1-amino-3-fluorocyclobutane-1-carboxylic acid; Axumin; F(18)-FACBC; F(18)1-amino-3-fluorocyclobutane-1-carboxylic acid; F-FACBC; GE-148 (18F); GE-148 F-18; NMK 36; NMK-36; NMK36 cpd; anti-(18F)FACBC; cyclobutanecarboxylic acid, 1-amino-3-(fluoro-18F)-, trans-; fluciclovine (18F); fluciclovine F 18

Networked: 41 relevant articles (1 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclobutanes
        fluciclovine F-18: 41
- Carboxylic Acids: 973
  - fluciclovine F-18: 41

Experts

1.	Goodman, Mark M: 16 articles (01/2019 - 03/2009)
2.	Schuster, David M: 15 articles (01/2022 - 12/2011)
3.	Nieh, Peter T: 8 articles (01/2019 - 12/2011)
4.	Savir-Baruch, Bital: 7 articles (01/2018 - 12/2011)
5.	Osunkoya, Adeboye O: 6 articles (01/2019 - 01/2013)
6.	Jani, Ashesh B: 5 articles (01/2022 - 05/2014)
7.	Master, Viraj A: 5 articles (01/2019 - 12/2011)
8.	Halkar, Raghuveer K: 5 articles (09/2016 - 12/2011)
9.	Oka, Shuntaro: 5 articles (11/2015 - 07/2013)
10.	Shirakami, Yoshifumi: 5 articles (11/2015 - 07/2013)

Related Diseases

1.	Neoplasms (Cancer) 11/01/2022 - "Axumin (18F-Fluciclovine) PET imaging in men exhibiting no clinically significant cancer on initial negative biopsy of PI-RADS 4 and 5 regions of interest." 06/01/2014 - "The significant anti-[(18)F]FACBC uptake in T/B cells may cause false-positives in some cancer patients who undergo FACBC-positron emission tomography (PET)." 06/01/2014 - "The low anti-[(18)F]FACBC accumulation in granulocytes/macrophages may be advantageous in discriminating inflamed regions from tumors. " 03/01/2014 - "(18)F FACBC PET/CT shows higher uptake in intraprostatic tumor foci than in normal prostate tissue; however, (18)F FACBC uptake in tumors is similar to that in BPH nodules. " 03/01/2014 - "Combined (18)F FACBC and MR imaging yielded positive predictive value of 82% for tumor localization, which was higher than that with either modality alone (P < .001). "
2.	Prostatic Neoplasms (Prostate Cancer) 11/07/2023 - "As piflufolastat F 18 has been approved in the United States (US) for this indication, this modeling study assessed the cost effectiveness of piflufolastat F 18 versus fluciclovine F-18, gallium68-PSMA-11 (PSMA 11), and SOC imaging (a mix of bone scans, computed tomography, and magnetic resonance imaging) for the diagnosis and staging of prostate cancer from a US healthcare system perspective. " 11/01/2022 - "The objective of the study was to determine whether Axumin (18F-Fluciclovine) PET/MRI informs the decision to perform an early repeat biopsy of PI-RADS 4/5 region of interest (ROI) exhibiting no clinically significant prostate cancer (csPCa) on initial biopsy. " 04/01/2023 - "18 F-fluciclovine (Axumin; Blue Earth Diagnostics, Ltd, Oxford, United Kingdom) PET has shown value in detecting biochemical recurrent prostatic cancer. " 12/01/2021 - "18F-fluciclovine (Axumin) PET/CT has been widely used for the evaluation of biochemically recurrent prostate cancer following prior treatment. " 04/01/2021 - "The PET tracer 18F-fluciclovine (Axumin) was recently approved in the United States and Europe for men with suspected prostate cancer recurrence following prior treatment. "
3.	Carcinoma (Carcinomatosis) 05/01/2014 - "A total of 93 patients met study inclusion criteria who underwent anti-3-[(18)F]FACBC positron emission tomography-computerized tomography plus (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for suspected recurrent prostate carcinoma within 90 days. " 10/01/2013 - "The purpose of this study is to determine the uptake characteristics of anti-3-[(18)F]FACBC in lung carcinoma and if this radiotracer may help characterize pulmonary lesions. " 09/01/2018 - "Selective modification of fluciclovine (18F) transport in prostate carcinoma xenografts." 04/01/2015 - "Retrospective review of 14 patients who underwent follow-up anti-3-[(18)F]FACBC positron emission tomography-X-ray computed tomography (PET-CT) for prostate carcinoma recurrence. " 05/01/2014 - "Better diagnostic performance was noted for anti-3-[(18)F]FACBC positron emission tomography-computerized tomography than for (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for prostate carcinoma recurrence. "
4.	Brain Neoplasms (Brain Tumor) 12/01/2022 - "The study aims to evaluate whether combined 18 F-FACBC PET/MRI could provide additional diagnostic information compared with MRI alone in brain metastases. " 12/01/2022 - "18 F-FACBC PET should be further evaluated in recurrent brain metastases." 12/01/2022 - "Eighteen patients with newly diagnosed or suspected recurrence of brain metastases received dynamic 18 F-FACBC PET/MRI. " 12/01/2022 - "Diagnostic Value of 18 F-FACBC PET/MRI in Brain Metastases." 12/01/2022 - "However, 18 F-FACBC PET/MRI did not improve detection of brain metastases compared with MRI but might detect tumor tissue beyond contrast enhancement on MRI. "
5.	Lymphadenitis (Adenitis) 08/01/2014 - "In the biodistribution study, the uptake ratios of PLM-to-lymphadenitis in lesional lumbar and inguinal LNs were 0.97-1.57 and 1.47-2.08 at 15 and 60min post-anti-[(18)F]FACBC injection respectively. "

Related Drugs and Biologics

1.	Amino Acids
2.	Acids
3.	Prostate-Specific Antigen (Semenogelase)
4.	Carboxylic Acids
5.	Androgens
6.	fluciclovine F-18
7.	Radiopharmaceuticals
8.	Investigational Drugs
9.	Yttrium
10.	Methionine (L-Methionine)

Related Therapies and Procedures

1.	Lymph Node Excision (Lymph Node Dissection)
2.	Prostatectomy (Retropubic Prostatectomy)
3.	Radiotherapy
4.	Therapeutics